Skip to content

RXRX

Recursion Pharmaceuticals, Inc.

Key figures

MetricLast 12 months5-year CAGR
Revenue$68M+79.9%
Gross profit$20M−1.2%
Operating income−$495M—
Net income−$476M—
EPS−$0.90—
Free cash flow−$312M—